-
GammaDelta Therapeutics Announces Publication of New Data in Nature Immunology Describing the Independent Immune Function of Gamma Delta (gd) T Cell Receptors
Findings support development of γδ T cells for gastrointestinal diseases GammaDelta Therapeutics Ltd, an emerging biotech company developing novel immunotherapies for cancer and other diseases announced today the publication in Nature Immunology of new data examining the biological role of gamma delta (γδ) T cell receptors. The findings arose from an ongoing collaboration between GammaDelta […]
-
Q BioMed Takes the Stage in the Expanded Access Debate at European Early and Managed Access Program Conference
Q BioMed Orphan Drug VP, who started the first Expanded Access Program Database asked to Speak on Panels and run Roundtable at the Early and Managed Access Program Conference in the UK from October 22nd to 24th 2018 Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, is pleased to announce that Robert Derham, a […]
-
Q BioMed Takes the Stage in the Expanded Access Debate at European Early and Managed Access Program Conference
Q BioMed Orphan Drug VP, who started the first Expanded Access Program Database asked to Speak on Panels and run Roundtable at the Early and Managed Access Program Conference in the UK from October 22nd to 24th 2018 Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, is pleased to announce that Robert Derham, a […]
-
Q BioMed Takes the Stage in the Expanded Access Debate at European Early and Managed Access Program Conference
Q BioMed Orphan Drug VP, who started the first Expanded Access Program Database asked to Speak on Panels and run Roundtable at the Early and Managed Access Program Conference in the UK from October 22nd to 24th 2018 Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, is pleased to announce that Robert Derham, a […]
-
Carrick Therapeutics In-Licenses Targeted Ovarian Cancer Treatment From BTG and Appoints George Golumbeski as Chairman
Exclusive worldwide licence deal adding to Carrick”s rapid pipeline expansion Preparations for pivotal studies underway Dr. George Golumbeski appointed as Chairman of the Board Carrick Therapeutics, a biopharmaceutical company focusing on the innovative research and development of transformative oncology medicines, has today announced that it has licensed exclusive worldwide rights to develop and commercialise BTG945, […]
-
Bitumen Market to Witness Enhanced Application Into Adhesives, Waterproofing, Insulation and Roadways till 2024 | Million Insights
The global Bitumen Market is estimated to develop at a substantial CAGR for the duration of the prediction due to growing usage in Adhesives, Waterproofing, Insulation, and Roadways. Speedy expansion in developing marketplaces has contributed to growth in substructure actions. The combination of carbon-based fluids that are black, sticky, solvable in carbon disulfide and extremely […]
-
CRB opens second office in Europe, hires Bernd Müller
‘The opening of operations for CRB in Germany strategically aligns with our clients” growth in the region over the last decade and allows us to serve their needs locally,’ CRB president, Ryan Schroeder, said. ‘In addition, Germany”s commitment to research and manufacturing in the life science industry makes it a natural fit for the expertise […]
-
Regen BioPharma, Inc. Reports Activation of Immune Cells by Its NR2F6 Small Molecule Inhibitors
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP), reports its researchers have identified a series of small molecule drugs that inhibit NR2F6 and also activate human immune cells ex-vivo. Evidence provided by studies suggest that NR2F6 represses the body”s immune response against tumors; therefore inhibiting NR2F6 may lead to enhanced immune response against cancerous tumor […]
-
Avison Young Acquires Market-Leading U.K. Firm Wilkinson Williams LLP, Opens New Office in London’s West End; 16 Members Join
Purchase expands Avison Young”s U.K. footprint and adds eight Principals Mark E. Rose, Chair and CEO of Avison Young, the world”s fastest-growing, private and Principal-led, global commercial real estate services firm, announced today that it has acquired market-leading U.K. firm Wilkinson Williams LLP and opened a new office in London”s West End. Since its inception in 1991, Wilkinson […]
-
4D Presents at IHMC 2018
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of live biotherapeutics, today announced that the Company”s Chief Scientific Officer, Dr. Alex Stevenson, has spoken at the International Human Microbiome Consortium (IHMC) 2018 on the importance of function in the development of live biotherapeutics. ‘Ahead of World Microbiome Day, IHMC 2018 is an […]